by Paul | 29th April 2026 | News
Robert J. Dempsey, MBA, Chief Executive Officer, to present at Eyecelerator Raj Patil, PhD, Chief Scientific Officer, to present at ARVO London and New York, NY, April 29, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing...
by Paul | 30th October 2024 | News
London and New York, NY, October 30, 2024. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy,...
by Paul | 15th August 2024 | News
London and New York, NY, August 15, 2024 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular...
